Oxford vaccine trial paused over side effects
AstraZeneca maintains that the exact nature of the illness is currently unknown and such pauses are common during the development of a vaccine.
- Sep 9, 2020
In addition to being one of the nine vaccine candidates which have reached the critical last leg of clinical trials, the Oxford vaccine was also found to provide “double immunity” against the COVID-19 in the safety results of its Phase I trials. While the Oxford vaccine did trigger the production of both the protective antibodies and “Killer T-cells” in the body, it should be noted that the incidence of mild side-effects were quite high.
According to a report published in the Lancet, 70 per cent of the volunteers who were dosed with the Oxford vaccine candidate experienced fatigue, mild fever, chills, headache and muscle ache. The reachers had maintained that all the side-effects were manageable and most of them resolved on their own.
About The Author -